Lipella Pharmaceuticals company info

What does Lipella Pharmaceuticals do?
Lipella Pharmaceuticals (NASDAQ:LIPO) focuses on the research and development of innovative pharmaceutical solutions directed towards the treatment of urological disorders. Their primary efforts are aimed at creating novel therapies designed to improve patient outcomes and quality of life. With ongoing projects targeting conditions like hemorrhagic cystitis and overactive bladder, Lipella is dedicated to addressing unmet medical needs. The company's objectives encompass the advancement of their drug candidates through clinical trials, with the ultimate goal of securing regulatory approval and bringing these treatments to market. Their work represents a commitment to pioneering new paths in urology care, striving to fill the gap in effective treatment options available to patients worldwide.
Lipella Pharmaceuticals  company media
Company Snapshot

Is Lipella Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Lipella Pharmaceuticals employ?

people
Employees
5

What sector is Lipella Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Lipella Pharmaceuticals ?

location pin
Head Office
Pittsburgh, United States

What year was Lipella Pharmaceuticals founded?

founded flag
Year Founded
2005
What does Lipella Pharmaceuticals specialise in?
/Urological Products /Bladder Therapies /Tumor Treatments /Liposomal Products /Cancer Immunotherapy /Drug Development

What are the products and/or services of Lipella Pharmaceuticals ?

Overview of Lipella Pharmaceuticals offerings
LP-10, a novel formulation of tacrolimus for treating hemorrhagic cystitis, focusing on reducing inflammation and bleeding in the bladder.
Research into novel formulations and applications of existing drugs for urological conditions, aiming at improving patient care and outcomes.
Development of therapies targeting bladder cancer, with an emphasis on non-invasive treatments to improve survival rates and quality of life for patients.
Innovative drug delivery systems designed to enhance the efficacy and reduce the side effects of urological medications.
Partnerships with academic and research institutions to advance the understanding of urological diseases and develop new therapeutic strategies.
Community outreach and patient education initiatives aimed at raising awareness about bladder health and available treatment options.

Who is in the executive team of Lipella Pharmaceuticals ?

Lipella Pharmaceuticals leadership team
  • Dr. Jonathan  Kaufman M.B.A., Ph.D.
    Dr. Jonathan Kaufman M.B.A., Ph.D.
    Co-Founder, Chairman, CEO, President, Secretary & Treasurer
  • Dr. Michael B. Chancellor M.D.
    Dr. Michael B. Chancellor M.D.
    Co-Founder, Chief Medical Officer & Director
  • Mr. Douglas  Johnston CPA
    Mr. Douglas Johnston CPA
    Chief Financial Officer
  • Ms. Michele  Gruber
    Ms. Michele Gruber
    Director of Operations
  • Katie  Johnston
    Katie Johnston
    Controller